Literature DB >> 6274906

Testosterone secretion by cultured arrhenoblastoma cells: suppression by a luteinizing hormone-releasing hormone agonist.

S W Lamberts, J M Timmers, R Oosterom, T Verleun, F H de Jong.   

Abstract

A patient with virilization was studied. The basal urinary excretion of 17-ketosteroids was at the upper limit of normal, but the plasma testosterone concentration was greatly elevated. Testosterone secretion could be stimulated by hCG, suppressed by dexamethasone, and was not affected by ACTH. At operation, an arrhenoblastoma of the left ovary was found. Isolated tumor cells in culture secreted testosterone. The addition of a LRH agonist (10 ng/ml) suppressed the secretion of testosterone by 50% (P less than 0.01). The inhibiting effect of a LRH agonist on steroidogenesis suggests that LRH receptors were present on this tumor and that treatment with LRH agonists might be beneficial in patients with metastatic steroid hormone-secreting ovarian and testicular tumors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6274906     DOI: 10.1210/jcem-54-2-450

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Hormonal aspects of ovarian malignancy.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1984-03       Impact factor: 5.344

2.  New prospects for luteinising hormone releasing hormone as a contraceptive and therapeutic agent.

Authors:  H M Fraser
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

3.  A virilizing Leydig cell tumor of the ovary associated with stromal hyperplasia under gonadotropin control.

Authors:  J A Marcondes; M Nery; B B Mendonça; S A Hayashida; H W Halbe; F M Carvalho; B L Wajchenberg
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

4.  Neuroendocrineimmunology (NEI) at the turn of the century: towards a molecular understanding of basic mechanisms and implications for reproductive physiopathology.

Authors:  B Marchetti; M C Morale; F Gallo; N Batticane; Z Farinella; M Cioni
Journal:  Endocrine       Date:  1995-12       Impact factor: 3.633

5.  Leydig cell tumor estrogen secretion: suppression by a gonadotropin releasing hormone agonist.

Authors:  P Valensi; C Coussieu; E Killian; N Tran-Quang; J R Attali; J Sebaoun
Journal:  J Endocrinol Invest       Date:  1991 Jul-Aug       Impact factor: 4.256

6.  Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.

Authors:  P N Plowman; R I Nicholson; K J Walker
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

7.  Noninvasive test for the diagnosis of ovarian hormone-secreting-neoplasm in postmenopausal women.

Authors:  Ilan Cohen; Dan Nabriski; Ami Fishman
Journal:  Gynecol Oncol Rep       Date:  2015-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.